🔎 Trials Near Me

ホーム › 急性骨髄性白血病 › ペンシルベニア

ペンシルベニアにおける急性骨髄性白血病の臨床試験

ペンシルベニア内の拠点で、急性骨髄性白血病に関する45件の研究が参加者を募集しています。

ペンシルベニア内の都市

公式研究テキスト(英語)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  • Thomas Jefferson University Hospital, Philadelphia
被験者募集中第2相
60歳以上 · 全性別 · 2026/10/02更新 · NCT07437950

Assessment of Geriatric Evaluations Impact on New AML Guidance

  • Abramson Cancer Center at University of Pennsylvania, Philadelphia
被験者募集中観察研究
50歳以上 · 全性別 · 2026/10/02更新 · NCT05909501

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Geisinger Medical Center, Danville
  • 他7件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Hospital of Philadelphia, Philadelphia
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Milton S Hershey Medical Center, Hershey
  • 他4件
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Thomas Jefferson University, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
  • University of Pittsburgh Medical Center, Pittsburgh
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Milton S Hershey Medical Center, Hershey
  • 他6件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  • Children's Hospital of Philadelphia, Philadelphia
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh
被験者募集中第1相
21歳以下 · 全性別 · 2026/09/23更新 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Milton S Hershey Medical Center, Hershey
  • 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Geisinger Medical Center, Danville
  • Thomas Jefferson University Hospital, Philadelphia
  • UPMC Hillman Cancer Center, Pittsburgh
  • 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Milton S Hershey Medical Center, Hershey
  • 他6件
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • 他3件
被験者募集中第3相
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • University of Pennsylvania, Philadelphia
被験者募集中第1/2相
30 Days · 全性別 · 2026/09/16更新 · NCT04065399

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • Spoknwrd Clinical Trials Inc., Easton
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06824168

A Study of BGB-11417 in Participants With Myeloid Malignancies

  • Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT04771130

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

  • UPENN Perelman Center for Advanced Medicine, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06846606

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Geisinger Medical Center, Danville
  • Children's Hospital of Philadelphia, Philadelphia
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh
被験者募集中第3相
1歳〜25歳 · 全性別 · 2026/09/04更新 · NCT07022678

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

  • Cancer Care Associates of York, York
被験者募集中観察研究
0歳以上 · 全性別 · 2026/09/02更新 · NCT07154823

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Pittsburgh PA-PITT, Pittsburgh
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  • US-Pittsburgh PA-PITT, Pittsburgh
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/01更新 · NCT07223814

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • 他3件
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Children's Hospital of Philadelphia, Philadelphia
被験者募集中第3相
29 Days – 21 Years · 全性別 · 2026/08/24更新 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Pennsylvania, Philadelphia
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

  • UMPC Hillman Cancer Center, Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07565220

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

  • UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06529731

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

  • University of Pennsylvania, Philadelphia
被験者募集中第2/3相
18歳〜80歳 · 全性別 · 2026/08/05更新 · NCT06788756

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • Children's Hospital of Philadelphia, Philadelphia
被験者募集中第1相
1歳〜30歳 · 全性別 · 2026/08/03更新 · NCT06177067

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

  • Penn Medicine Abramson Cancer Center, Philadelphia
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/10更新 · NCT05442216

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

  • University of Pennsylvania, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/09更新 · NCT05945849

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

  • Children's Hospital of Philadelphia, Philadelphia
被験者募集中
25歳以下 · 全性別 · 2026/07/08更新 · NCT03810196

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

  • Children's Hospital of Philadelphia, Philadelphia
被験者募集中第1相
0歳〜29歳 · 全性別 · 2026/07/07更新 · NCT07464951

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Penn State Milton S. Hershey Cancer Center, Hershey
  • Children's Hospital of Philadelphia, Philadelphia
  • Children's Hospital of Pittsburgh, Pittsburgh
  • 他3件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

  • Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/24更新 · NCT04068597

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

  • University of Pennsylvania, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/14更新 · NCT06222580

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

  • Pennsylvania State University Hershey Medical Center, Hershey
被験者募集中第1相
21歳以下 · 全性別 · 2026/04/22更新 · NCT05101551

Massage Impact on Sleep in Pediatric Oncology

  • Children's Hospital of Philadelphia, Philadelphia
被験者募集中
12歳〜21歳 · 全性別 · 2026/04/15更新 · NCT06892158

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Sidney Kimmel Comprehensive Cancer Center, Philadelphia
  • Allegheny Health Network, Pittsburgh
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555

Phase IB/II of CPX-351 for Relapse Prevention in AML

  • University of Pennsylvania, Philadelphia
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/23更新 · NCT04990102

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

  • Thomas Jefferson University Hospital, Philadelphia
被験者募集中第1相
12歳以上 · 全性別 · 2026/03/16更新 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Hospital of the University of Pennsylvania, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。